Switching from Innovator to Biosimilar (Subsequent Entry) Infliximab: Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines


( Last Updated : January 18, 2017)
Project Line:
Health Technology Review
Project Sub Line:
Summary with Critical Appraisal
Project Number:
RC0836-000

Details


Question


  1. What is the clinical effectiveness and safety of switching from innovator infliximab to subsequent entry infliximab for patients with rheumatoid arthritis?

  2. What is the clinical effectiveness and safety of switching from innovator infliximab to subsequent entry infliximab for patients with ankylosing spondylitis?  

  3. What is the clinical effectiveness and safety of switching from innovator infliximab to subsequent entry infliximab for patients with plaque psoriasis?  

  4. What is the clinical effectiveness and safety of switching from innovator infliximab to subsequent entry infliximab for patients with Crohn’s Disease?

  5. What is the clinical effectiveness and safety of switching from innovator infliximab to subsequent entry infliximab for patients with ulcerative colitis?  

  6. What is the clinical effectiveness and safety of switching from innovator infliximab to subsequent entry infliximab for patients with psoriatic arthritis?  

  7. What is the cost-effectiveness of switching from innovator infliximab to subsequent entry infliximab?  

  8. What are the evidence-based guidelines regarding switching from innovator infliximab to subsequent entry infliximab?


Key Message

Findings from observational studies on patients with rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, Crohn’s Disease, or ulcerative colitis suggest that switching from infliximab treatment to infliximab biosimilar may be possible without compromising efficacy or safety. However the findings need to be interpreted with caution as for most conditions the findings were from single studies, some of which were small in size. No relevant studies on patients with psoriatic arthritis were identified.   Two budget impact studies and a systematic review highlight potential for cost savings after the introduction of biosimilars to the market. No evidence-based guidelines regarding switching from innovator infliximab to subsequent entry infliximab were identified.